BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.

By K. Alsop, S. Fereday, C. Meldrum, A. Defazio, C. Emmanuel, J. George, A. Dobrovic, M. Birrer, P. Webb, C. Stewart and 4 more. Journal of Clinical Oncology, 2012

1,156 citations recorded by the source corpus.

Subfields: Genetics, Oncology, Reproductive Medicine

View Paper: https://www.semanticscholar.org/paper/8a2c60ee1c9ce32c0900f648484df45e650c1cf0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Lindsey A. Torre
2. A. D’Andrea
3. A. Jemal
4. Roman Yelensky
5. R. Siegel

In Oncology

1. R. Siegel
2. A. Jemal
3. K. Miller
4. C. DeSantis
5. Lindsey A. Torre
6. A. D’Andrea
7. G. Shapiro
8. Raphael Ceccaldi

In Reproductive Medicine

1. A. D’Andrea
2. A. Oza
3. Jonathan A. Ledermann
4. Raphael Ceccaldi
5. C. Sessa
6. D. Querleu
7. A. González-Martín
8. L. Kelland

Citations in the corpus

• Homologous recombination deficiency: Exploiting the fundamental vulnerability of ovarian cancer (2015, background): “6% of HGSOCs (16, 23, 24), whereas somatic BRCA1 and BRCA2 mutations have been identified in 6% to 7% of high-grade serous EOCs (16, 25).”
• Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. (2017, background): “Ovarian cancer is the fifth leading cause of cancer death in women in both the United States and European Union.(1,2) Mutations in one allele of BRCA1 or BRCA2 (BRCA) accompanied by”
• Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018, background): “Family history plays a very important role in the development of ovarian cancer, although in a recent study 44% patients with high-grade serous ovarian cancer and a germline BRCA mutation did not report a family history of cancer [3].”
• ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease (2019, result): “289 BRCA-mutated patients in particular, but also BRCA WT patients, may respond to re-challenge with platinum-based chemotherapy, even with a TFIp of <6 months.(47) For both groups, the response rate to platinum-based chemotherapy on relapse within 6 months after first-line treatment was higher comp”
• Ovarian Cancer Statistics, 2018 (2018, background): “and BRCA2 account for almost 40% of ovarian cancer cases in women with a family history of the disease.(55) Rare moderate penetrance gene mutations for epithelial ovarian cancer include those in BRCA1-interacting protein C-terminal helicase 1 (BRIP1), RAD51 paralog C (RAD51C), and RAD51D.”
• Inherited Mutations in Women with Ovarian Carcinoma (2016, neutral): “%) in BRCA1, 9 (16.7”